UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL				
OMB Number:	3235-0287				
Estimated average burden					
hours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)														
Name and Address of Reporting Person * Martin Robert L.				2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]							5. I	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 01/24/2018						X	X Officer (give title below) Other (specify below) SVP, Nonclinical & Manuf.					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEWARK												om med of a	Tore than one it	seporting reason		
(City))	(State)	(Zip)	Table I - Non-Derivative Securities Acq						Acquired	quired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, if r) any (Month/Day/Year)		ate, if (1	(Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D)		of (D) Own Train	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		I (Ownership of Brorm:	eneficial wnership	
Reminder: R	deport on a se	eparate line for each	Table II - 1	Derivativ	e Se	ecurities	Acqui	Perso contai form o	ns who ined in the displays	this forr a curre or Bene	m are not ently valid ficially Ov	required to OMB cor	of informa to respond ntrol numb	l unless the		74 (9-02)
Derivative Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code r) (Instr. 8)		5. Number of		options, convertible secur 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisa	Expi ble Date	ration	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (right to buy)	\$ 11.69	01/24/2018		Α		125,00	0	(1)	01/2	23/2028	Common Stock	125,000	\$ 0	125,000	D	
Report	ting O	wners				Relation	achine									

Barrandina Omman Nama / Addinas		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Martin Robert L. C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BOULEVARD NEWARK, CA 94560			SVP, Nonclinical & Manuf.					

Signatures

/s/ Sujal Shah, as attorney-in-fact	01/26/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.